Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 14 of 14 publications.
Skip to main content
Horn L, Bauml J, Forde PM, Davis KL, Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 2019 Feb;128(2019):74-90. doi: 10.1016/j.lungcan.2018.12.003
Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007
Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018 Oct;124:310-6. doi: 10.1016/j.lungcan.2018.07.042.
Alford SH, Divine G, Chao C, Habel LA, Janakiraman N, Wang Y, Feigelson HS, Scholes D, Roblin D, Epstein MM, Engel L, Havstad S, Wells K, Yood MU, Fortuny J, Johnson CC, Cancer Research Network Lymphoma Study Group. Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis. Cancer Causes Control. 2018 Jan;29(1):143-56. doi: 10.1007/s10552-017-0987-7
Du XL, Parikh RC, Lairson DR. Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007–2010 after the 2006 introduction of bevacizumab. Lung Cancer. 2015 Dec;90(3):442-50.
Davis KL, Goyal RK, Able SL, Brown J, Li L, Kaye JA. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Lung Cancer. 2015 Feb;87(2):176-85. doi: 10.1016/j.lungcan.2014.11.002
Lupo PJ, Danysh HE, Skapek SX, Hawkins DS, Spector LG, Zhou R, Okcu MF, Papworth K, Erhardt EB, Grufferman S. Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children's Oncology Group. Cancer Causes Control. 2014 Jul;25(7):905-13. doi: 10.1007/s10552-014-0390-6.
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
Carsin AE, Drummond FJ, Black A, van Leeuwen PJ, Sharp L, Murray LJ, Connolly D, Egevad L, Boniol M, Autier P, Comber H, Gavin A. Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland. Cancer Causes Control. 2010 Sep;21(9):1523-31. doi: 10.1007/s10552-010-9581-y
Hoyo C, Berchuck A, Halabi S, Bentley RC, Moorman P, Calingaert B, Schildkraut JM. Anthropometric measurements and epithelial ovarian cancer risk in african–american and white women. Cancer Causes Control. 2005 Oct 1;16(8):955-63.
Harris DH, Bates JH, Cress R, Tabnak F, Wright WE. Stage of breast cancer diagnosis among medically underserved women in California receiving mammography through a state screening program. Cancer Causes Control. 2004 Sep;15(7):721-9.
Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles. Cancer Causes Control. 2002 Nov;13(9):807-11.
Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Wolf MK. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy - Lung (FACT-L): analysis of ECOG 5592 data. Poster presented at the 7th Central European Lung Cancer Conference; June 2001. Prague, Czech Republic. [abstract] Lung Cancer. 2001 May; 32(Suppl 1):52.
Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Bonomi P, Wolf MK. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy (lung) (FACT-L): analysis of ECOG 5592 data. Lung Cancer. 2001;373-6.